Market Overview

UPDATE: Sterne Agee Reiterates On Salix Pharmaceuticals Ahead Of FDA Panel Vote

Related SLXP
UCERIS 2mg Rectal Foam For The Induction Of Remission Of Mild-To-Moderate Distal Ulcerative Colitis Granted Tentative Approval By FDA
Credit Suisse Sees Downside In Shares Of Salix Pharmaceuticals, Ltd.

In a report published Thursday, Sterne Agee analyst Shibani Malhotra reiterated a Buy rating on Salix Pharmaceuticals Ltd. (NASDAQ: SLXP), and raised the price target from $126.00 to $130.00.

In the report, Sterne Agee noted, “We reiterate our Buy thesis on SLXP in front of the FDA panel vote, expected later this afternoon, regarding the use of Relistor as a possible treatment for opioid-induced constipation. A path to development can add around $6 to our fair value of $130 for SLXP, while a negative outcome should have little impact given the minimal expectations going into this event. We are more focused on the data from TARGET III for Xifaxan in IBS-D (early July) as a meaningful positive catalyst for the stock.”

Salix Pharmaceuticals Ltd. closed on Wednesday at $113.42.

Latest Ratings for SLXP

Sep 2014Credit SuisseInitiates Coverage onUnderperform
Aug 2014JMP SecuritiesMaintainsMarket Outperform
Aug 2014Cantor FitzgeraldMaintainsBuy

View More Analyst Ratings for SLXP
View the Latest Analyst Ratings

Posted-In: Shibani Malhotra Sterne AgeeAnalyst Color Price Target Analyst Ratings


Related Articles (SLXP)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters